IST:MEDTR (Turkey)
Â
Class B
₺
27.96
-0.060 (-0.21%)
Jul 10
Business Description
MEDITERA TIBBI MALZEME SANAYI VE TICARET AS
ISIN : TREMDTR00028
Share Class Description:
IST:MEDTR: Class BTotal Employee Number:
782Description
MEDITERA TIBBI MALZEME SANAYI VE TICARET AS is engaged in the manufacture of anesthesia and intensive care circuits, the installation, operation, and design of oncology drug preparation and delivery systems, production, sales, and technical service of infusion pumps and sets, and the manufacture of biocidal products.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 15.22 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.18 | |||||
Interest Coverage | 2.56 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 3.93 | |||||
Beneish M-Score | -2.58 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 21.7 | |||||
3-Year EBITDA Growth Rate | -10.1 | |||||
3-Year Book Growth Rate | 24.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 29.73 | |||||
9-Day RSI | 34.14 | |||||
14-Day RSI | 37.5 | |||||
3-1 Month Momentum % | 4.96 | |||||
6-1 Month Momentum % | 5.69 | |||||
12-1 Month Momentum % | -7.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.58 | |||||
Quick Ratio | 2.49 | |||||
Cash Ratio | 0.9 | |||||
Days Inventory | 115.55 | |||||
Days Sales Outstanding | 81.48 | |||||
Days Payable | 71.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.9 | |||||
Dividend Payout Ratio | 1.68 | |||||
3-Year Dividend Growth Rate | -47.7 | |||||
Forward Dividend Yield % | 1.62 | |||||
5-Year Yield-on-Cost % | 0.88 | |||||
Shareholder Yield % | 1.77 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 30.83 | |||||
Operating Margin % | 3.39 | |||||
Net Margin % | 0.61 | |||||
EBITDA Margin % | 6.37 | |||||
FCF Margin % | 14.59 | |||||
OCF Margin % | 22.08 | |||||
ROE % | 0.62 | |||||
ROA % | 0.5 | |||||
3-Year ROIIC % | -8.93 | |||||
ROC (Joel Greenblatt) % | -0.03 | |||||
ROCE % | -0.02 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 186.41 | |||||
Price-to-Owner-Earnings | 6.56 | |||||
PS Ratio | 1.2 | |||||
PB Ratio | 0.84 | |||||
Price-to-Tangible-Book | 0.87 | |||||
Price-to-Free-Cash-Flow | 8.17 | |||||
Price-to-Operating-Cash-Flow | 5.42 | |||||
EV-to-EBIT | -3069.55 | |||||
EV-to-EBITDA | 12.55 | |||||
EV-to-Revenue | 0.79 | |||||
EV-to-FCF | 5.69 | |||||
Price-to-GF-Value | 0.64 | |||||
| Price-to-Net-Current-Asset-Value | 2.17 | |||||
Earnings Yield (Greenblatt) % | -0.03 | |||||
FCF Yield % | 15.34 | |||||
Forward Rate of Return (Yacktman) % | 15.9 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MEDITERA TIBBI MALZEME SANAYI VE TICARET AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₺) | 2,789.191 | ||
| EPS (TTM) (₺) | 0.15 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -0.12 | ||
| 3-Year Sortino Ratio | -0.17 | ||
| Volatility % | 32.58 | ||
| 14-Day RSI | 37.5 | ||
| 14-Day ATR (₺) | 0.836411 | ||
| 20-Day SMA (₺) | 29.269 | ||
| 12-1 Month Momentum % | -7.92 | ||
| 52-Week Range (₺) | 26 - 37.96 | ||
| Shares Outstanding (Mil) | 94.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MEDITERA TIBBI MALZEME SANAYI VE TICARET AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MEDITERA TIBBI MALZEME SANAYI VE TICARET AS Stock Events
| Event | Date | Price (₺) | ||
|---|---|---|---|---|
| TRY 0.113445 Cash Dividend | 2026-12-28 | In 170 days | ||
| TRY 0.113445 Cash Dividend | 2026-10-27 | In 108 days | ||
| TRY 0.113445 Cash Dividend | 2026-07-29 | In 18 days | ||
| TRY 0.084034 Cash Dividend | 2025-12-31 | 27.92 (+0.07%) | ||
| TRY 0.084034 Cash Dividend | 2025-10-27 | 30.24 (+3.42%) | ||
| TRY 0.084034 Cash Dividend | 2025-07-28 | 35.50 (+0.74%) | ||
| TRY 0.294118 Cash Dividend | 2024-10-23 | 46.24 (+2.76%) | ||
| 3.5:1 Stock Split | 2022-02-22 | 12.51 (+1.30%) |
Show
Entries
MEDITERA TIBBI MALZEME SANAYI VE TICARET AS Frequently Asked Questions
What is MEDITERA TIBBI MALZEME SANAYI VE TICARET AS(IST:MEDTR)'s stock price today?
The current price of IST:MEDTR is ₺27.96. The 52 week high of IST:MEDTR is ₺37.96 and 52 week low is ₺26.00.
When is next earnings date of MEDITERA TIBBI MALZEME SANAYI VE TICARET AS(IST:MEDTR)?
The next earnings date of MEDITERA TIBBI MALZEME SANAYI VE TICARET AS(IST:MEDTR) is .
Does MEDITERA TIBBI MALZEME SANAYI VE TICARET AS(IST:MEDTR) pay dividends? If so, how much?
The Dividend Yield %  of MEDITERA TIBBI MALZEME SANAYI VE TICARET AS(IST:MEDTR) is 0.9% (As of Today), Highest Dividend Payout Ratio of MEDITERA TIBBI MALZEME SANAYI VE TICARET AS(IST:MEDTR) was 4.07. The lowest was 0.3. And the median was 1.24. The  Forward Dividend Yield % of MEDITERA TIBBI MALZEME SANAYI VE TICARET AS(IST:MEDTR) is 1.62%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on MEDITERA TIBBI MALZEME SANAYI VE TICARET AS
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers